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Renal amyloidosis caused by a novel stop-codon mutation in protein that aggregates to form amyloid fibrils. These
the apolipoprotein A-II gene. proteins may be the result of single nucleotide change,
Background. Although apolipoprotein A-II (apoA-II) asso- deletion or insertion in the gene coding for the amyloidciated amyloidosis has been described in the senescent acceler-
precursor protein. To date, hereditary amyloidosis hasated mouse (SAM) model of aging, so far there has been no
been associated with over 70 mutations in TTR, 9 muta-report of human apoA-II amyloidosis except for a recent report
of renal amyloidosis resulting from a stop-codon to glycine tions in apoA-I, 4 in fibrinogen A-chain, 2 in lysozyme,
mutation of apoA-II. The mechanisms of amyloid formation 2 in gelsolin, and 1 in cystatin C [7]. Apolipoprotein A-II
in human apoA-II amyloidosis are not clear. (apoA-II) is one of the major components of plasmaMethods. A 46-year-old Caucasian male with proteinuria
high-density lipoprotein (HDL) and is mainly producednoted at 42 years of age was studied. Renal biopsy revealed
amyloid deposition in glomeruli. DNA analysis of genes known in the liver and small intestine with N-terminus pre- and
to be associated with hereditary renal amyloidosis revealed no pro-peptides. Mature apoA-II is composed of 77 amino
abnormalities. To elucidate the type of his amyloidosis, apoA- acid residues and, in plasma, exists mainly as a disulfide-
II gene and plasma apoA-II were examined.
linked dimer with a molecular weight of approximatelyResults. DNA analysis revealed heterozygosity for a G to
17 kD [8]. While apoA-II was well known to form amy-C transversion at the second position of the stop-codon of
apoA-II gene, suggesting a stop to serine substitution at codon loid fibrils in the senescence accelerated mouse (SAM)
78. Western blot analysis and amino acid sequence analysis of model of aging [9], apoA-II amyloidosis had never been
the patient’s plasma apoA-II showed both normal apoA-II and reported in humans. Moreover, no mutant human apoA-variant apoA-II with a 21-amino acid residue extension at the
II proteins have been described. Recently, Benson et alC-terminus.
Conclusions. These results indicate that the patient’s amy- identified a novel type of amyloid composed of a variant
loid fibrils were derived from apoA-II and the amyloidogenesis apoA-II isolated from kidney of an affected patient in
is likely to be closely linked to the peptide extension at the a kindred originally reported in 1973 [10, 11]. Although
C-terminus of variant apoA-II. The pathogenesis of human
the causative relationship between the mutant apoA-IIapoA-II amyloidosis is different from that of SAM.
and amyloid fibril formation has been recognized, there
have been no other reports of human apoA-II amy-
Hereditary systemic amyloidosis may be caused by loidosis. The mechanisms of amyloid fibril formation
mutations in a number of plasma proteins including trans- from apoA-II and similarities or differences between
thyretin (TTR), cystatin C, apolipoprotein A-I (apoA-I), human and SAM have not been addressed.
gelsolin, fibrinogen A-chain, and lysozyme [1–6]. Each This study reports a patient with renal amyloidosis
type of amyloidosis is inherited as an autosomal-domi- who has a novel variant of apoA-II, and discusses possi-
nant disease and is associated with a structurally altered ble mechanisms of amyloid formation from variant
apoA-II.
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autosomal-dominant disease, amyloid fibril formation, lipoprotein, glo-
merulosclerosis. The proband, a 46-year-old Caucasian male, was first
seen at age 42 to evaluate proteinuria and a serum creati-Received for publication April 20, 2001
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Fig. 1. Histopathology of the patient’s biopsied kidney. Congo red-stained section revealed amyloid deposition in the glomeruli (A) and vascular
walls (B, arrow), which by polarization microscope showed typical green birefringence of amyloid. No tissue remained for immunohistochemistry.
present in the walls of medium-sized blood vessels (Fig. DNA studies searching for mutations in genes known
1B); Significant past history was a serum creatinine deter- to be associated with systemic amyloidosis including
mination of 1.3 mg/dL at age 35. An abdominal fat pad TTR, apoA-I, lysozyme and fibrinogen A-chain failed
aspirate was positive for amyloid deposition, and amy- to reveal any abnormalities.
loid was noted in blood vessel walls of a bone marrow Subsequently, the patient has continued to work with-
biopsy. There were no signs of neuropathy, cardiomeg- out medical problems except for hypertension that has
aly, or hepato-splenomegaly on physical examination. been controlled medically.
Family history revealed that the patient’s mother died
at age 67 of cancer of the breast, and the father died at METHODS
age 75 of cancer of the urinary bladder. One sister and
DNA isolationthree half siblings were reported to be in good health.
Genomic DNA was isolated from peripheral bloodThe patient’s two children, ages four years and eight
leukocytes using a standard phenol/chloroform method.months, were well. Evaluation for systemic amyloidosis
revealed normal electrocardiogram and echocardio-
Single-strand conformation polymorphism analysisgram. There was no evidence of monoclonal gammopa-
Exons 3 and 4 of the apoA-II gene were examined bythy on immunofixation of serum or urine. There was
single-strand conformation polymorphism (SSCP) an-only modest proteinuria (595 mg/24 h), and creatinine
clearance was 47 mL/min. alysis using oligonucleotide primers as follows: exon
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3, (A2E3F) TGC TGT GGA CCC AGC TGA and 4 (yielding a 161 bp product). After purification of PCR
products by QIAquick PCR purification kit (Qiagen),(A2E3R) GAA CCC CTT GCC CTG AGA yielding a
217 bp product; exon 4, (A2E4F) CTA ATC CCC TCA 12.5 L of amplified DNA was added to 1 L of NlaIII
(New England Biolabs, Beverly, MA, USA), 1.6 L ofCCT A and (A2E4R) GGA AGA CAA TGG TCT G
yielding a 161 bp product. Polymerase chain reaction its specific buffer, 0.16L of 100 bovine serum albumin
(BSA) and 0.74 L of distilled water, and incubated for(PCR) was done in a total volume of 50 L, containing
5 L of 10  PCR buffer (100 mmol/L Tris-HCl, pH three hours at 37C. The samples were electrophoresed
through 3% (wt/vol) Nusieve GTG agarose gel (FMC8.3, 500 mmol/L KCl, 12 mmol/L MgCl2), 8 L of 1.25
mmol/L dNTP, 15 pmol of each primer, 2.5 units of Taq BioProducts, Rockland, ME, USA), stained with ethid-
ium bromide and photographed under ultraviolet light.polymerase (Sigma, St. Louis, MO, USA) and 100 ng of
genomic DNA. Amplification was performed using a
Western blot analysis of plasmaPerkin-Elmer Thermal Cycler (Norwalk, CT, USA) for
40 cycles consisting of denaturing at 95C for 30 seconds, Plasma samples in sodium dodecyl sulfate (SDS)
buffer were heated in a boiling water bath for 10 minutesannealing at 63C (exon 3) or 60C (exon 4) for one
minute, and extension at 72C for 30 seconds. Six micro- with or without 5% 2-mercaptoethanol and electropho-
resed on a 16.5% Tris-Tricine Ready gel (Bio-Rad, Her-liters of polymerase chain reaction (PCR) product was
diluted in 20 L of SSCP buffer containing 98% for- cules, CA, USA) for two hours at 100 V. Subsequently,
proteins were transferred for one hour at 90 V onto nitro-mamide, 0.05% xylene cyanol FF, 0.05% bromophenol
blue, 10 mmol/L NaOH and 10 mmol/L ethylenedi- cellulose membrane (Trans-Blot Transfer Medium;
Bio-Rad). After blocking the membrane with 5% nonfataminetetraacetic acid (EDTA), and heated at 95C for
five minutes. Six microliters of diluted samples was elec- dry milk in phosphate-buffered saline (PBS), pH 7.4, the
apoA-II bands were detected with sheep anti-humantrophoresed on a 15% polyacrylamide gel including
10% glycerol in the Tris-glycine buffer, pH 8.3. Single- apoA-II (1:1000 in 5% milk; Boehringer Mannheim,
Mannheim, Germany). Alkaline phosphatase-conjugatedstranded PCR products were visualized by silver staining
[12]. donkey anti-sheep IgG (Sigma) was used as the second
antibody (1:1000 in 5% milk). The immunoblots were
Direct DNA sequence analysis visualized with a reaction to NBT/BCIP Alkaline phos-
phatase substrate (Sigma).DNA was analyzed by the direct sequencing of exons
3 and 4 of the apoA-II gene. PCR was done as indicated
Isolation of plasma apoA-II and amino acidin the last section of this article. The PCR product was
sequence analysispurified by QIAquick PCR purification kit (Qiagen, Va-
lencia, CA, USA) according to the manufacturer’s proto- Plasma apoA-II was isolated according to a method
to isolate high density lipoprotein (HDL) described pre-col. Sequencing reaction was performed by using 1.0 L
of purified PCR-product as the template and the Thermo viously with some modifications [15]. Five milliliters of
plasma was adjusted to a density of 1.21 g/mL with KBrSequence [-33P]ddNTP radiolabeled terminator cycle
sequencing kit (USB, Cleveland, OH, USA). Samples and ultracentrifuged at 100,000 rpm for six hours (TL-
100 ultracentrifuge; Beckman, Palo Alto, CA, USA).were electrophoresed on a 6% polyacrylamide gel at 45
W for three hours using a glycerol tolerant gel buffer, The top layer was collected, dialyzed against distilled
water, and lyophilized. The sample was dissolved in 8dried and exposed to Kodak X-Omat film (Eastman Ko-
dak, Rochester, NY, USA). mol/L guanidine HCl containing dithiothreitol (DTT),
alkylated with iodoacetic acid, and fractionated on a
Restriction fragment length polymorphism Sepharose CL6B column (Pharmacia, Uppsala, Swe-
(RFLP) analysis den). Fractions were combined into three pools ac-
cording to the absorbance at 280 nm, dialyzed againstIn the absence of a spontaneous creation of an endonu-
clease restriction site by the TGA to TCA mutation in distilled water, and lyophilized. Protein samples were
analyzed by sodium dodecyl sulfate-polyacrylamide gelthe stop codon of the apoA-II gene, a PCR-induced
mutation restriction analysis (IMRA) was performed electrophoresis (SDS-PAGE) and Western blot using
anti-human apolipoprotein A-II antibody (Boehringer[13]. A mutation primer (A2S78) corresponding to nucle-
otides 2151 to 2129 of the apoA-II nucleotide sequence Mannheim) as indicated previously in this article. The
Sepharose CL6B pool III was digested with trypsin and[14] with an A instead of T at the second position from
the 3 end (5-GGA AGA CAA TGG TCT GGA CAC the resulting peptides were fractionated on a Beckman
Ultrasphere-ODS high-pressure liquid chromatographyAT-3) was used to create a restriction site for NlaIII
(CATG) only in the mutant gene PCR products. PCR (HPLC) column. Samples were subjected to Edman deg-
radation on an ABI 473A protein sequencer using thewas performed with A2E4F and A2S78 primers under
the same conditions as in the DNA sequencing of exon manufacturer’s standard cycle programs.
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Fig. 2. DNA sequence analysis of exon 4 of
the apoA-II gene. Both guanine and cytosine
are present at the second position of apoA2
stop codon (arrow) in the DNA sequence of
the patient.
RESULTS
DNA analysis
The SSCP analysis revealed an abnormally migrating
band for apoA-II exon 4 PCR products of the patient
in contrast to those of normal controls (data not shown).
Direct DNA sequencing of the exon 4 PCR product
showed a single base substitution in the stop codon for
the apoA-II gene (TGA to TCA) indicating a stop to
serine substitution at codon 78 followed by 60 bases
before a new stop codon (Fig. 2) [14]. No other mutations
were found in exons 3 and 4 of apoA-II gene, which
encode the entire pro- and mature apoA-II protein, in Fig. 3. NlaIII restriction site analysis of apoA-II exon 4 polymerase
this patient. chain reaction (PCR) products. The G to C transversion at the second
position of stop-codon of apoA2 creates a NlaIII restriction site withinRestriction fragment length polymorphism analysis of
the 161 bp PCR amplified fragment when coupled with mutagenesisthe 161 bp PCR product from A2E4F and A2S78 primers primer (A2S78). Enzyme digestion gives fragments of 137 bp and 24
revealed that the patient had the NlaIII recognition site bp (the latter is not visible) for the mutant allele. The PCR-amplified
fragment (161 bp) of the patient (lane 3) was incompletely digested,associated with the guanine to cytosine mutation at the
indicating that he is heterozygous for this mutation. The fragmentssecond position of the stop codon (Fig. 3). Electrophore- from two normal controls were not digested with NlaIII (lanes 1 and
sis of the digested PCR product in the patient gave a 2). M, 100 bp molecular ruler DNA size standard (Bio-Rad).
digestion band of 137 bp in addition to the normal 161
bp band indicating heterozygosity for this mutation. To
exclude the possibility that the G to C mutation might
apoA-II (Fig. 4). In the patient in this study, positivebe a polymorphism, we analyzed DNA from 50 unrelated
bands migrating with molecular weight correspondingindividuals (100 alleles). None had the G to C mutation.
to dimeric normal apoA-II, heterodimeric apoA-II with
Characterization of plasma apoA-II normal and variant molecules, and dimeric variant apoA-
II were identified in nonreducing conditions. In the pres-Plasma samples obtained from this patient, a patient
ence of reducing conditions, Western analysis revealedwith variant apoA-II (stop to glycine mutation of apoA-
two bands (8 and 10 kD) corresponding to normalII) described previously [10], and a normal individual
were studied by Western blot analysis using anti-human apoA-II monomer and the larger variant apoA-II mono-
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these patients varied from adolescence to the fifth decade
and they died in the fifth to sixth decades. While autopsy
studies revealed that amyloid accumulation was present
in most visceral organs, except for central nervous system
and peripheral nerves, renal amyloid was the most prom-
inent feature [11]. The severity of amyloid deposition in
the liver, heart, and spleen was moderate and limited
mainly to vascular walls. Benson et al isolated the amy-
loid fibrils from the kidney obtained from an autopsied
patient in that family and identified that the amyloid
fibrils were derived from variant apoA-II caused by a
stop codon mutation (TGA; stop to GGA; glycine) [10].
This mutation results in a 21-amino acid residue exten-
sion at the C-terminus of normal apoA-II protein.
In the present study, DNA analysis revealed that the
Fig. 4. Western blot with anti-human apolipoprotein A-II (apoA-II) affected individual described here was heterozygous for
antibody of plasma. Nonreduced denatured plasma samples were run a novel stop-codon mutation in the apoA-II gene (TGA
in lanes 1 (patient), 2 (patient reported previously [10]), and 3 (normal
to TCA) that causes substitution of serine for the stop-control). Reduced denatured plasma samples were run in lanes 4 (pa-
tient), 5 (patient reported previously [10]), and 6 (normal control). N: codon at codon 78. Amino acid sequence analysis of the
normal apoA-II monomeric form. V: variant apoA-II monomeric form. patient’s plasma apoA-II showed not only normal apoA-
VV, NV, NN: dimeric forms of apoA-II.
II, but also variant apoA-II with a 21-residue extension
at the C-terminus. This 21-amino acid extension was
completely identical to that in the patient with variant
mer, respectively. These results were consistent with apoA-II described by Benson et al, except for serine at
those in the patient with stop to glycine mutation of residue 78 [10].
apoA-II [10]. Those extra bands were not detected in a The clinical picture of the patient described here re-
normal individual. sembles that in patients with variant apoA-II reported
The top layer of the patient’s plasma after being ad- previously [10, 11]. During the clinical course, the
justed to a density of 1.21 g/mL and ultracentrifugation most noticeable clinical manifestation was nephropathy
was dissolved in 8 mol/L guanidine HCl in the presence caused by renal amyloidosis in both the patient described
of DTT, alkylated with iodoacetic acid, and fractionated and the patients with stop to glycine mutation in the
on a Sepharose CL6B column (Fig. 5). While two major apoA-II gene. Moreover, the distinctive feature of amy-
retarded peaks (pools II and III) were found, SDS- loidosis in both families is that affected individuals do
PAGE analysis and Western blot analysis indicated that not have significant dysfunction of other visceral organs,
most normal and variant apoA-II were contained in pool including the heart, liver, and peripheral nerves due to
III (Fig. 6). Amino acid sequence analysis of pool III amyloid deposition, although amyloid accumulation was
after tryptic digestion showed that both normal apoA- seen systemically in affected patients of both families.
II and variant apoA-II, with serine at position 78 and a While the mechanism of how amyloid proteins have or-
20 amino acid extension, were present (Fig. 7). The N-ter- gan specificity that leads to variation in clinical features is
minal residues 1–3 tryptic peptide was not detected, since unknown, the non-neuropathic, nephropathic syndrome
N-terminal glutamine is cyclized to pyroglutamate and seems to be the prominent feature for apoA-II amy-
blocked to Edman analysis. This result confirmed the loidosis. The clinical features in both kindreds are similar
findings of DNA sequence analysis.
to fibrinogen A-chain and lysozyme amyloidosis in
terms of nephropathy without neuropathy [5, 6, 17]. Al-
DISCUSSION though there is no clear difference in the onset of amy-
loidosis among apoA-II, fibrinogen A-chain, and lyso-Recently, human apoA-II amyloidosis was first identi-
zyme amyloidosis, the latter forms (fibrinogen A-chainfied in an affected member of a family originally reported
and lysozyme) usually show more extensive hepatic andin 1973 as an unusual form of hereditary nonneuropathic
splenic involvement.amyloidosis [11], similar to that described by Ostertag
Despite recent biochemical and molecular-genetic ad-[16]. Clinically, the most prominent manifestation in all
vances, possible mechanisms of amyloid fibril formationaffected patients of that family was renal failure charac-
in apoA-II amyloidosis are not clear. In comparison withterized by proteinuria, edema, hypertension, and azote-
the previously reported family with variant apoA-IImia. Symptoms caused by amyloidosis of other visceral
(stop to glycine mutation) [10, 11], the affected patientsorgans including the heart, liver, spleen, and peripheral
nerves were absent [10, 11]. The onset of the disease in in both families have a novel 21-amino acid peptide in
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Fig. 5. Chromatogram of top layer of pa-
tient’s plasma after ultracentrifugation, solu-
bilized in 8 mol/L guanidine HCl on a Sepha-
rose CL6B column equilibrated and eluted
with 4 mol/L guanidine HCl, 0.05 mol/L Tris,
pH 8.2. Fractions were pooled as indicated by
the bars.
to HDL caused by variant apoA-II with extended se-
quence without lipid-binding capability could alter its
metabolism and accelerate amyloid fibril formation [10].
The same thing may be hypothesized for amyloid fibril
formation in variant apoA-II with stop to serine muta-
tion in this study, although the precise conformational
change with both types of variant apoA-II (stop to gly-
cine and stop to serine mutation) has not been fully
understood.
Higuchi et al suggested importance of amino acid sub-
stitution in the N-terminal region of apoA-II for develop-
ment of amyloid in the SAM, since the strain of mouse
(SAMP) with the highest incidence of amyloidosis has
a glutamine for proline substitution at the fifth residue
from the N-terminus of apoA-II [23, 24]. However, hu-
Fig. 6. SDS-PAGE analysis and Western blot with anti-human man normal apoA-II with a proline in the fifth position
apoA-II antibody on Sepharose CL6B pools. SDS-PAGE analysis and
is similar to apoA-II of SAM mice resistance to amy-Western blot analysis showing that most normal (8 kD) and variant
apoA-II (10 kD) is contained in pool III. Abbreviations are: N, normal loidogenesis (SAMR), and affected patients in both fam-
apoA-II monomeric form; V, variant apoA-II monomeric form. ilies did not have a mutation at the fifth residue. There-
fore, it is unlikely in the human that the N-terminal
structure of the molecule plays an important role in its
tendency to form amyloid fibrils [10]. Also, in humancommon, although the first residue of that 21-residue
apoA-II amyloid patients, deposited amyloid fibrilspeptide (glycine or serine) is different. To date, there
are composed of only full-length variant apoA-II [10],have not been reports of human apoA-II amyloidosis
whereas mature apoA-II and pro-apoA-II were detectedcaused by other mutations except for the stop-codon
in amyloid fibrils of SAM [25]. In addition, heavy amy-site. It is likely, therefore, that the role of human apoA-
loid deposition is seen in the liver, spleen, and heart asII as a precursor of amyloid fibrils is closely related to
well as the kidney in SAM [26]. Hence, the pathogenesisthe extension of the protein at the C-terminus. Similar
of apoA-II related-amyloid formation in human is likelycases of amyloid fibril formation caused by novel peptide
to differ from amyloid formation in the SAM model.sequences at the C-terminus have been identified with
In the present study, the patient had no family historyfibrinogen A-chain [18, 19], ABri in familial British
of amyloidosis. Since DNA for analysis was limited todementia [20], and ADan in familial Danish dementia
only the patient, it could not be determined whether[21].
some asymptomatic carriers exist in this family or thisThe new peptide sequence at the C-terminus in variant
stop to serine mutation was caused by de novo mutation.apoA-II with stop to glycine mutation is predicted to
In the apoA-II amyloidosis family recently reported, thecontain an -helix that is different from the three class
amyloid showed autosomal dominant inheritance [10],A amphipathic helices, important for lipid binding [22].
Benson et al emphasized that decreased binding capacity similar to all other types of hereditary amyloidosis [7].
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ization of a senile amyloid-related antigenic substance (apoSASSAM)The patient described here was heterozygous for the
from mouse serum: ApoSASSAM is an apoA-II apolipoprotein ofapoA-II mutation associated with amyloidosis. Accord- mouse high density lipoproteins. J Biol Chem 261:12834–12840,
1986ingly, the chance that each of his children may have
10. Benson MD, Liepnieks JJ, Yazaki M, et al: A new human heredi-inherited this mutant allele is 50%. Careful observation
tary amyloidosis: The result of a stop-codon mutation in the apoli-
will be required for family members, especially his chil- poprotein AII gene. Genomics 72:272–277, 2001
11. Weiss SW, Page DL: Amyloid nephropathy of Ostertag with spe-dren. Finally, this newly recognized apoA-II amyloidosis
cial reference to renal glomerular giant cells. Am J Pathol 72:447–provides further knowledge of human amyloidogenesis
460, 1973
and most likely will be of value in evaluating a number of 12. Wallace AJ, Williamson P, Mountford RC, Ramsden SC: Non-
isotopic detection of microsatellite repeats using silver staining.kindreds worldwide with as yet unexplained autosomal
J Med Genet 30:346–347, 1993dominant amyloidosis, especially with nephropathy but
13. Zeldenrust SR, Benson MD: A new test for detection of the His58
no neuropathy. variant transthyretin allele in hereditary amyloidosis: Creation of
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Fig. 7. Amino acid sequence and cDNA sequence of human apoA-II from initiate codon to poly-A sequence. The translated amino acid sequence
is given below the cDNA and the 21-amino acid residue extension resulting from mutation in the stop codon (residues 78 to 98) is indicated.
Arrows show the sequence of plasma apoA-II identified by amino acid sequence analysis of tryptic peptides. The dotted line indicates the 21-
amino acid residue extension in variant apoA-II.
